Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Caribou Biosciences (CRBU) Operating Income (2020 - 2025)

Caribou Biosciences has reported Operating Income over the past 6 years, most recently at -$28.5 million for Q4 2025.

  • Quarterly Operating Income rose 26.81% to -$28.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$148.3 million through Dec 2025, up 10.97% year-over-year, with the annual reading at -$148.3 million for FY2025, 10.97% up from the prior year.
  • Operating Income was -$28.5 million for Q4 2025 at Caribou Biosciences, up from -$29.4 million in the prior quarter.
  • Over five years, Operating Income peaked at -$13.2 million in Q1 2021 and troughed at -$47.6 million in Q2 2025.
  • The 5-year median for Operating Income is -$30.0 million (2022), against an average of -$30.3 million.
  • Year-over-year, Operating Income plummeted 607.94% in 2021 and then surged 44.86% in 2023.
  • A 5-year view of Operating Income shows it stood at -$20.4 million in 2021, then tumbled by 49.86% to -$30.6 million in 2022, then fell by 22.45% to -$37.4 million in 2023, then dropped by 3.83% to -$38.9 million in 2024, then increased by 26.81% to -$28.5 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Operating Income are -$28.5 million (Q4 2025), -$29.4 million (Q3 2025), and -$47.6 million (Q2 2025).